Skip to main content
Equibles
SION $3.49 +1.75%
SION logo
SION · Sionna Therapeutics, Inc.
Track SION — free

Use SION with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SION.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.49 +0.06 (+1.75%) Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing states the doubt was alleviated.

“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$155.16M
Shares
45.24M
Volume · Nov 12 411.81K Avg daily vol (3M) 1.35M
All webcasts

Earnings call · FY2026 Q3

Sionna Therapeutics, Inc. (SION) Q3 2026 Earnings Call

Concluded Nov 10, 2026
Nov 10, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Diluted EPS -$0.72
Net income -$32.42M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 10, 2026
Sionna plans to initiate the AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222 in the first quarter of 2027; $249.8 million in cash is expected to fund operations into the second half of 2029.
10-Q report · filed Nov 10, 2026
Sionna Therapeutics selected SION-451 + SION-2222 for the AscenSION CF Phase 2 trial, expected to begin in the first quarter of 2027. SION-719 missed its key endpoint, prompting an approximately 46% workforce reduction; cash of $249.8 million supports operations into the second half of 2029.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Nov 10, 2026 10-Q report Filed Nov 10, 2026
Full-screen source Call document

SION alerts

Sionna Therapeutics, Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →

Embed Sionna Therapeutics, Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview